- Home
- PFD vs STRO Comparison
PFD vs STRO Comparison
Compare PFD & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFD
- STRO
- Stock Information
- Founded
- PFD 1990
- STRO 2003
- Country
- PFD United States
- STRO United States
- Employees
- PFD N/A
- STRO N/A
- Industry
- PFD Investment Managers
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PFD Finance
- STRO Health Care
- Exchange
- PFD Nasdaq
- STRO Nasdaq
- Market Cap
- PFD 148.3M
- STRO 172.8M
- IPO Year
- PFD N/A
- STRO 2018
- Fundamental
- Price
- PFD $11.24
- STRO $1.87
- Analyst Decision
- PFD
- STRO Strong Buy
- Analyst Count
- PFD 0
- STRO 7
- Target Price
- PFD N/A
- STRO $12.14
- AVG Volume (30 Days)
- PFD 33.2K
- STRO 1.5M
- Earning Date
- PFD 01-01-0001
- STRO 11-13-2024
- Dividend Yield
- PFD 6.30%
- STRO N/A
- EPS Growth
- PFD N/A
- STRO N/A
- EPS
- PFD N/A
- STRO N/A
- Revenue
- PFD N/A
- STRO $160,955,000.00
- Revenue This Year
- PFD N/A
- STRO N/A
- Revenue Next Year
- PFD N/A
- STRO N/A
- P/E Ratio
- PFD N/A
- STRO N/A
- Revenue Growth
- PFD N/A
- STRO 230.90
- 52 Week Low
- PFD $8.53
- STRO $1.70
- 52 Week High
- PFD $11.18
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- PFD 41.53
- STRO 25.63
- Support Level
- PFD $11.05
- STRO $1.70
- Resistance Level
- PFD $11.80
- STRO $3.01
- Average True Range (ATR)
- PFD 0.19
- STRO 0.21
- MACD
- PFD -0.03
- STRO -0.05
- Stochastic Oscillator
- PFD 24.81
- STRO 11.36
About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.